



London, 27 June 1996  
EMEA/CVMP/114/96

## **PRESS RELEASE**

### **12th MEETING OF THE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS**

1. Under the chairmanship of Professor R. Kroker the twelfth meeting of the Committee for Veterinary Medicinal Products took place in London on 26-27 June 1996.

#### **CENTRALISED PROCEDURES**

2. The Committee appointed rapporteurs and co-rapporteurs for two new applications for recombinant vaccines, for which letters of intent have been received.

#### **SCIENTIFIC ADVICE**

3. Given the increased number of such requests for scientific advice, the Committee adopted a Standard Operating Procedure on Scientific Advice to be given for Innovative Veterinary Medicinal Products (EMEA/CVMP/098/96). This SOP will be made available to all interested parties.

#### **ESTABLISHMENT OF MAXIMUM RESIDUE LIMITS**

4. In light of the current chairman of the Safety of Residues Working Party, Dr Kevin Woodward, having to relinquish the post after the next meeting in July, the Committee elected Dr Gabriel Beechinor as the new chairman.
5. The Committee accepted the conclusion of the rapporteurs in consideration of one application for the establishment of a Maximum Residue Limit (MRL) for a new substance and agreed to recommend it for inclusion in Annex I of Council Regulation (EEC) No 2377/90.
6. The Committee also agreed with the proposal from the rapporteur to modify existing MRLs for one substance.
7. Rapporteurs and co-rapporteurs were appointed for the establishment of MRLs for 5 new substances, for the extension of one existing MRL to include a new species, and for the modification of another.

8. Regarding the establishment of maximum residue limits for applications received prior to 1 January 1995 by the European Commission and transferred then to the Agency, the Committee made the following recommendations:

	Annex I	Annex II	Annex III	Annex IV
New Substances (Article 6)	-	-	-	-
Old Substances (Article 7)	-	6	6	1

9. In addition, the status reports and the consolidated list of questions to the applicant for 13 old substances currently under evaluation were adopted.

#### **NOTES FOR GUIDANCE**

10. At the request of the Commission, the Committee initiated discussion on the need to broaden the scope of its Guidelines on Minor Species to include Salmonids in order to facilitate the establishment of MRLs for substances used in aquaculture.
11. The Committee continued its discussion on whether the current policy on Injection Site Residues should be amended and recommended further consultation on the subject with industry.

#### **INTERNATIONAL**

12. The Committee agreed on the topic leaders and experts to participate, on behalf of the European Union, to the Veterinary International Conference on Harmonisation (VICH).
13. The Committee agreed on the following substances to be considered for MRLs evaluation by JECFA as a priority : cyhalothrin, deltamethrin, florfenicol, griseofulvin, marbofloxacin, permethrin, phoxim and sarafloxacin.
14. The next meeting of the Committee will be held on 23-24 July 1996.

General information about EMEA, Guidelines, SOPs and EPAR (European Public Assessment Report) for centrally approved veterinary products are available on Internet and E-mail at the following addresses:

- E-mail: [mail@emea.eudra.org](mailto:mail@emea.eudra.org);
- Internet: [www.eudra.org](http://www.eudra.org).